PTP4A2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2211505	0.64	2/20
SCHEMBL5618661	0.61	2/20
SCHEMBL5618664	0.61	2/20
SCHEMBL4328828	0.61	2/20
SCHEMBL5164387	0.57	2/20
SCHEMBL8749247	0.57	2/20
SCHEMBL8995999	0.55	2/20
SCHEMBL9559164	0.55	2/20
SCHEMBL7794250	0.51	2/20
SCHEMBL8842877	0.51	2/20
SCHEMBL5595450	0.47	2/20
SCHEMBL4488546	0.46	2/20
SCHEMBL4488550	0.46	2/20
Glycine (SCHEMBL8218338)	0.46	2/20
SCHEMBL9553742	0.45	2/20
SCHEMBL1341449	0.44	2/20
SCHEMBL4325323	0.44	2/20
SCHEMBL4325325	0.44	2/20
SCHEMBL8361910	0.44	2/20
SCHEMBL8440705	0.44	2/20

Clinical trials — most relevant to PTP4A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy	PHASE3	UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases	PHASE2	COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Study of Constitutional Platelet Disease	nan	UNKNOWN
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies	nan	UNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Genetics and Psychopathology in the 22q11 Deletion Syndrome	nan	UNKNOWN
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Markers and Mechanisms of Macrovascular Disease in IDDM	nan	COMPLETED
Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation	nan	COMPLETED
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)	nan	RECRUITING
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies	nan	NOT_YET_RECRUITING
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTP4A2 binder may also engage these)

Protein	Name	Similarity
Q6P9X4	—	1.000	Q6P9X4 →
Q63739	—	1.000	Q63739 →
Q9TSM6	—	1.000	Q9TSM6 →
Q5R7J8	—	1.000	Q5R7J8 →
O70274	—	1.000	O70274 →
PTP4A1	Protein tyrosine phosphatase type IVA 1	1.000	landscape →
PTP4A3	Protein tyrosine phosphatase type IVA 3	0.999	landscape →
Q78EG7	—	0.999	Q78EG7 →
A2VDT1	—	0.998	A2VDT1 →
O61722	—	0.998	O61722 →
Q9D658	—	0.997	Q9D658 →
Q54DU9	—	0.993	Q54DU9 →
Q86IL4	—	0.992	Q86IL4 →
Q4CUJ8	—	0.991	Q4CUJ8 →
Q4QEZ7	—	0.986	Q4QEZ7 →
P0DOQ6	—	0.980	P0DOQ6 →
A0A7H0DN78	—	0.980	A0A7H0DN78 →
Q6GQJ8	—	0.979	Q6GQJ8 →
Q85297	—	0.979	Q85297 →
P0DOQ5	—	0.978	P0DOQ5 →
P24656	—	0.977	P24656 →
Q5XHB2	—	0.977	Q5XHB2 →
F4IDQ6	—	0.977	F4IDQ6 →
Q5XI69	—	0.977	Q5XI69 →
Q09632	—	0.977	Q09632 →
O04278	—	0.977	O04278 →
Q9M8K7	—	0.976	Q9M8K7 →
P20495	—	0.976	P20495 →
P50521	—	0.976	P50521 →
Q8IG39	—	0.976	Q8IG39 →